NCT03837626View on ClinicalTrials.gov

ENAC Blockade and Arterial Stiffness

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

October 5, 2024

Study Completion Date

April 30, 2025

Conditions
Overweight and ObesityInsulin Resistance
Interventions
DRUG

Placebo - Cap

6 months of 1 pill a day

DRUG

Amiloride Pill

Max dose of 5 mg a day for 6 months

Trial Locations (1)

65201

University of Missouri Hospital and Clinics, Columbia

All Listed Sponsors
lead

University of Missouri-Columbia

OTHER

NCT03837626 - ENAC Blockade and Arterial Stiffness | Biotech Hunter | Biotech Hunter